Back to Journals » Drug Design, Development and Therapy » Volume 13

In-vitro blood-brain barrier models for drug screening and permeation studies: an overview

Authors Bagchi S, Chhibber T, Lahooti B, Verma A, Borse V, Jayant RD

Received 21 June 2019

Accepted for publication 12 August 2019

Published 18 October 2019 Volume 2019:13 Pages 3591—3605

DOI https://doi.org/10.2147/DDDT.S218708

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Dr Yan Zhu


Sounak Bagchi,1 Tanya Chhibber,1 Behnaz Lahooti,1 Angela Verma,1 Vivek Borse,2 Rahul Dev Jayant1

1Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA; 2Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India

Correspondence: Rahul Dev Jayant
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, 1406 S. Coulter Street, Suite 1104, Amarillo, TX 79106, USA
Tel +1 806 414 9154
Fax +1 806 356 4034
Email rd.jayant@ttuhsc.edu

Abstract: The blood-brain barrier (BBB) is comprised of brain microvascular endothelial central nervous system (CNS) cells, which communicate with other CNS cells (astrocytes, pericytes) and behave according to the state of the CNS, by responding against pathological environments and modulating disease progression. The BBB plays a crucial role in maintaining homeostasis in the CNS by maintaining restricted transport of toxic or harmful molecules, transport of nutrients, and removal of metabolites from the brain. Neurological disorders, such as NeuroHIV, cerebral stroke, brain tumors, and other neurodegenerative diseases increase the permeability of the BBB. While on the other hand, semipermeable nature of BBB restricts the movement of bigger molecules i.e. drugs or proteins (>500 kDa) across it, leading to minimal bioavailability of drugs in the CNS. This poses the most significant shortcoming in the development of therapeutics for CNS neurodegenerative disorders. Although the complexity of the BBB (dynamic and adaptable barrier) affects approaches of CNS drug delivery and promotes disease progression, understanding the composition and functions of BBB provides a platform for novel innovative approaches towards drug delivery to CNS. The methodical and scientific interests in the physiology and pathology of the BBB led to the development and the advancement of numerous in vitro models of the BBB. This review discusses the fundamentals of BBB structure, permeation mechanisms, an overview of all the different in-vitro BBB models with their advantages and disadvantages, and rationale of selecting penetration prediction methods towards the critical role in the development of the CNS therapeutics.

Keywords: blood-brain barrier, BBB, brain microvascular endothelial cells, BMECs, tight junctions, TJs, proteins, central nervous system, CNS, induced pluripotent cells, iPSCs, in-silico prediction methods

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]